POSSIBLE DISCONTINUATION OF THERAPIES IN INFLAMMATORY RHEUMATIC DISEASES

Clinical and Experimental Rheumatology

Guest editors
T. Pincus, J. Braun, A. Kavanaugh, J.S. Smolen

Sponsored by the
NYU Post-Graduate Medical School

Supported by educational grants from:
Amgen, Inc., and Horizon Pharma, Inc.

CME Release date: November 1, 2013
CME Expiration date: February 28, 2014
Target Audience
Rheumatologists

Course Description
This supplement for the journal Clinical and Experimental Rheumatology is the 14th in an annual series entitled ‘Contemporary Topics in Rheumatic Diseases’.

Statement of Need
The need to examine diverse reports from many sources concerning evidence for and against discontinuation of therapies, primarily focused on biological therapies, has been recognised in a survey of rheumatologists. It was chosen as the optimal topic for 2013 for the series of annual supplements of Clinical and Experimental Rheumatology. The Supplement aims to include scholarly discussions of possible discontinuation of therapies in inflammatory rheumatic diseases, including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, spondyloarthropathies, ankylosing spondylitis, and related conditions, as well as paediatric juvenile arthritis.

Educational Objectives
At the conclusion of this activity, participants should be able to:

- Recognise the evidence that suggests discontinuation of therapies might be considered for certain patients in whom control of severe inflammation has been achieved.
- Recognise evidence that suggest discontinuation of therapies should not be considered in any patients in whom control of severe inflammation has been achieved.
- Formulate treatment plans for the use of biological therapies and possible discontinuation based on systematic knowledge of risk vs. benefit ratio rather than anecdotal considerations.

Method of Participation
To receive up to 10.25 CME credits, read this supplement, which should take 10.25 hours of your time, complete the evaluation and post-test and submit to the NYU Post-Graduate Medical School (instructions enclosed). A minimum passing grade of 70% is required.
This activity is valid for credit from November 1, 2013 through February 28, 2014.

Faculty Credentials
C.F. Allaart, MD
Department of Rheumatology
Leiden University Medical Center
Leiden, The Netherlands

Dr. med Xenofon Baraliakos
Rheumazentrum Ruhrgebiet
Ruhr-University Bochum
Herne, Germany

Prof. Dr. Jürgen Braun
Professor of Rheumatology
Ruhr-University Bochum
Herne, Germany

Prof. Roberto Caporali
Associate Professor of Rheumatology
University of Pavia
Head, Early Arthritis Clinic
IRCCS S. Matteo Foundation
Pavia, Italy

Oliver FitzGerald, MD, FRCPI, FRCP
Consultant Rheumatologist and Newman Clinical Research Professor
St. Vincent’s University Hospital and Conway Institute for Biomolecular Research
University College Dublin
Dublin, Ireland

Philip S. Helliwell, MD
Senior Lecturer in Rheumatology
Chapel Allerton Hospital, Leeds
Consultant Rheumatologist
St. Luke’s Hospital
Bradford, UK

Arthur Kavanaugh, MD
Professor of Clinical Medicine
University of California San Diego
LaJolla, CA, USA
Disclosure Statement

The NYU Post-Graduate Medical School adheres to ACCME Essential Areas and policies, including the Standards for Commercial Support, regarding industry support of continuing medical education. In order to resolve any identified conflicts of interest, disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships as well as the discussion of unlabelled or unapproved use of any drug, device or procedure by the faculty is listed below.

C.F. Allart, MD – Author
reports no relevant financial relationships.

Dr. med Xenofon Baraliakos – Author
serves on an Advisory Board for AbbVie, Inc.,
Merck-Sharpe and Dohme, Pfizer, Inc., Chugai
Pharmaceutical Co. Ltd. and Novartis
Pharmaceutical Corporation.

Prof. Dr. Jürgen Braun – Planner and Author
reports no relevant financial relationships.

Prof. Roberto Caporali – Author
reports no relevant financial relationships.

Oliver Fitzgerald, MD, FRCP, FRCP – Author
reports no relevant financial relationships.

Philip S. Helliwell, MD – Author
reports no relevant financial relationships.

Arthur Kavanaugh, MD – Planner and Author
is the recipient of research funding from
AbbVie, Inc., Amgen, Inc., Janssen Biotech,
Roche Laboratories, Pfizer, Inc. and UCB, Inc.

Dr. med Uta Kiltz – Author
reports no relevant financial relationships.

Prof. Raashid Luqmani – Author serves as a
consultant to GlaxoSmithKline and Chemocentryx, Inc.
Dr. Luqmani’s article includes discussion of the
unlabelled or unapproved use of a drug, device
or procedure.